ADPA-2M4CD8 is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADPA-2M4CD8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADP-A2M4CD8 is under development for the treatment of solid tumors including platinum-resistant ovarian cancer, urothelial carcinoma, endometrial cancer, esophageal cancer, melanoma, esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), peritoneal cancer, fallopian tube cancer and head and neck cancer. The therapeutic candidate comprises of CD8 alpha co-receptor alongside the autologous genetically modified engineered TCR that targets MAGE-A4. It is a next-generation of ADP-A2M4 which is administered by parenteral route. It is developed based on SPEAR T-cell platform.
It was under development for synovial sarcoma, myxoid, round cell liposarcoma and bladder cancer.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics (Adaptimmune), formerly Adaptimmune Therapeutics is a clinical stage bio pharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform that engineers the T-cells to identify and exterminate cancer, including solid tumors. The company’s pipeline products include NY-ESO TCR for synovial sarcoma and multiple myeloma; MAGE A4 TCR for multiple solid tumors; AFP TCR for hepatocellular cancer; and MAGE-A10 TCR for bladder, melanoma, and head and neck cancer. The company has presence in the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of ADPA-2M4CD8’s drug-specific PTSR and LoA scores, buy the report here.